{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:06:07Z","timestamp":1751601967404,"version":"3.41.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ucl.2025.04.012","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T19:14:52Z","timestamp":1748286892000},"page":"315-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperoxaluria"],"prefix":"10.1016","volume":"52","author":[{"given":"Owen P.","family":"Cunneely","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feres","family":"Camargo Maluf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Fargue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean G.","family":"Assimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle D.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.ki.5002708","article-title":"24-h uric acid excretion and the risk of kidney stones","volume":"73","author":"Curhan","year":"2008","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib2","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/ndt\/gfad221","article-title":"Twenty-four-hour urine oxalate and risk of chronic kidney disease","volume":"39","author":"Puurunen","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamainternmed.2018.7980","article-title":"Association of urinary oxalate excretion with the risk of chronic kidney disease progression","volume":"179","author":"Waikar","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"7 Suppl 2","key":"10.1016\/j.ucl.2025.04.012_bib4","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1097\/01.ASN.0000070149.78399.CE","article-title":"The chronic renal insufficiency cohort (CRIC) study: design and methods","volume":"14","author":"Feldman","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ucl.2025.04.012_bib5","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1046\/j.1523-1755.2001.00746.x","article-title":"Twenty-four-hour urine chemistries and the risk of kidney stones among women and men","volume":"59","author":"Curhan","year":"2001","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ucl.2025.04.012_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1053\/j.ajkd.2006.09.004","article-title":"Body size and 24-hour urine composition","volume":"48","author":"Taylor","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ki.1996.27","article-title":"Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults","volume":"49","author":"Lemann","year":"1996","journal-title":"Kidney Int"},{"issue":"5064","key":"10.1016\/j.ucl.2025.04.012_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/bmj.1.5064.175","article-title":"The aetiology of primary hyperoxaluria","volume":"1","author":"Archer","year":"1958","journal-title":"Br Med J"},{"issue":"179","key":"10.1016\/j.ucl.2025.04.012_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/adc.35.179.108","article-title":"Clinical manifestations of primary hyperoxaluria","volume":"35","author":"Hall","year":"1960","journal-title":"Arch Dis Child"},{"issue":"Suppl 8","key":"10.1016\/j.ucl.2025.04.012_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ndt\/10.supp8.3","article-title":"Epidemiology of primary hyperoxaluria type 1. Societe de Nephrologie and the Societe de Nephrologie Pediatrique","volume":"10","author":"Cochat","year":"1995","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ndt\/18.2.273","article-title":"Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome","volume":"18","author":"van Woerden","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.ucl.2025.04.012_bib12","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/ndt\/10.12.2224","article-title":"Changing pattern of primary hyperoxaluria in Switzerland","volume":"10","author":"Kopp","year":"1995","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.ucl.2025.04.012_bib13","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2014070698","article-title":"Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/ndt\/gfab027","article-title":"Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2","volume":"37","author":"Singh","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib15","first-page":"316","article-title":"Clinical and economic impact of primary hyperoxaluria: a retrospective claims analysis","volume":"28","author":"Mucha","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ucl.2025.04.012_bib16","article-title":"Primary hyperoxaluria type 1 disease manifestations and healthcare utilization: a multi-country, online, chart review study","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.ucl.2025.04.012_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajhg.2016.03.026","article-title":"Mutations in SLC26A1 cause nephrolithiasis","author":"Gee","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0014-5793(86)80563-4","article-title":"Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I","volume":"201","author":"Danpure","year":"1986","journal-title":"FEBS Lett"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2025.04.012_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00240-014-0701-0","article-title":"Mechanisms of human kidney stone formation","volume":"43","author":"Evan","year":"2015","journal-title":"Urolithiasis"},{"issue":"12","key":"10.1016\/j.ucl.2025.04.012_bib20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/ki.2009.32","article-title":"The primary hyperoxalurias","volume":"75","author":"Hoppe","year":"2009","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00247-016-3723-7","article-title":"Primary hyperoxaluria: spectrum of clinical and imaging findings","volume":"47","author":"Strauss","year":"2017","journal-title":"Pediatr Radiol"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2025.04.012_bib22","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ckj\/sfab232","article-title":"Treatment of primary hyperoxaluria type 1","volume":"15","author":"Gupta","year":"2022","journal-title":"Clin Kidney J"},{"issue":"7","key":"10.1016\/j.ucl.2025.04.012_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s004310050649","article-title":"Primary hyperoxaluria type 2","volume":"156","author":"Kemper","year":"1997","journal-title":"Eur J Pediatr"},{"issue":"8","key":"10.1016\/j.ucl.2025.04.012_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrneph.2012.113","article-title":"An update on primary hyperoxaluria","volume":"8","author":"Hoppe","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ejhg.2012.139","article-title":"Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategies","volume":"21","author":"Beck","year":"2013","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.08000520","article-title":"Pathophysiology and treatment of enteric hyperoxaluria","volume":"16","author":"Witting","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ndt\/gfv005","article-title":"Enteric hyperoxaluria: an important cause of end-stage kidney disease","volume":"31","author":"Nazzal","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.soard.2005.07.002","article-title":"Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass","volume":"1","author":"Nelson","year":"2005","journal-title":"Surg Obes Relat Dis"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib29","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJM197307262890402","article-title":"Mechanism for hyperoxaluria in patients with ileal dysfunction","volume":"289","author":"Chadwick","year":"1973","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00365527809181746","article-title":"Evidence for excessive absorption of oxalate by the colon in enteric hyperoxaluria","volume":"13","author":"Modigliani","year":"1978","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jamcollsurg.2005.03.021","article-title":"Alterations in gastrointestinal physiology after Roux-en-Y gastric bypass","volume":"201","author":"Ponsky","year":"2005","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ucl.2025.04.012_bib32","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0016-5085(76)80318-6","article-title":"Effects of bile salts and fatty acids on the colonic absorption of oxalate","volume":"70","author":"Dobbins","year":"1976","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1053\/j.gastro.2017.01.004","article-title":"Steatorrhea and hyperoxaluria in severely obese patients before and after roux-en-Y gastric bypass","volume":"152","author":"Moreland","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.juro.2008.09.028","article-title":"Prevalence of hyperoxaluria after bariatric surgery","volume":"181","author":"Patel","year":"2009","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib35","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.surg.2010.11.015","article-title":"Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery","volume":"149","author":"Kumar","year":"2011","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jamcollsurg.2010.03.007","article-title":"Hyperoxaluria is a long-term consequence of Roux-en-Y Gastric bypass: a 2-year prospective longitudinal study","volume":"211","author":"Duffey","year":"2010","journal-title":"J Am Coll Surg"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.juro.2006.09.033","article-title":"Hyperoxaluria in kidney stone formers treated with modern bariatric surgery","volume":"177","author":"Asplin","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/nu16020264","article-title":"Intestinal oxalate absorption, enteric hyperoxaluria, and risk of urinary stone formation in patients with Crohn\u2019s disease","volume":"16","author":"Siener","year":"2024","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/00365527809181767","article-title":"Enteric hyperoxaluria: dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease","volume":"13","author":"Hylander","year":"1978","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib40","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.juro.2009.11.022","article-title":"Hypocitraturia and hyperoxaluria after Roux-en-Y gastric bypass surgery","volume":"183","author":"Maalouf","year":"2010","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1523-1755.2001.00488.x","article-title":"Contribution of dietary oxalate to urinary oxalate excretion","volume":"59","author":"Holmes","year":"2001","journal-title":"Kidney Int"},{"issue":"3 Pt 2","key":"10.1016\/j.ucl.2025.04.012_bib42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S0022-5347(17)40999-2","article-title":"Oxalate synthesis, transport and the hyperoxaluric syndromes","volume":"141","author":"Williams","year":"1989","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib43","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0022-5347(05)01001-3","article-title":"Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test","volume":"175","author":"Voss","year":"2006","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.ucl.2025.04.012_bib44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1681\/ASN.0000000000000176","article-title":"Endogenous oxalate synthesis and urinary oxalate excretion","volume":"34","author":"Fargue","year":"2023","journal-title":"J Am Soc Nephrol"},{"year":"2025","series-title":"Hyperoxaluria","author":"Shah","key":"10.1016\/j.ucl.2025.04.012_bib45"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.juro.2014.05.006","article-title":"Medical management of kidney stones: AUA guideline","volume":"192","author":"Pearle","year":"2014","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib47","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","article-title":"Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment","volume":"27","author":"Cochat","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5527\/wjn.v4.i2.235","article-title":"Primary and secondary hyperoxaluria: understanding the enigma","volume":"4","author":"Bhasin","year":"2015","journal-title":"World J Nephrol"},{"year":"2025","series-title":"24-hour urine testing for nephrolithiasis: interpretation and treatment guidelines","author":"Leslie","key":"10.1016\/j.ucl.2025.04.012_bib49"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","article-title":"Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope","volume":"19","author":"Groothoff","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib51","doi-asserted-by":"crossref","first-page":"88.e1","DOI":"10.1016\/j.jpurol.2023.10.001","article-title":"Distinguishing characteristics of pediatric patients with primary hyperoxaluria type 1 in PEDSnet","volume":"20","author":"Tasian","year":"2024","journal-title":"J Pediatr Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib52","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1053\/j.ajkd.2021.07.018","article-title":"Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review","volume":"79","author":"Demoulin","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.ucl.2025.04.012_bib53","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ekir.2018.07.020","article-title":"Secondary oxalate nephropathy: a systematic review","volume":"3","author":"Lumlertgul","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib54","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.semnephrol.2022.04.012","article-title":"Sex Differences and the risk of kidney stones","volume":"42","author":"Ferraro","year":"2022","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ucl.2025.04.012_bib55","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.amsu.2020.11.002","article-title":"Relationship of spot urine oxalate to creatinine ratio and 24 hours urinary oxalate excretion in patients with urolithiasis","volume":"60","author":"Hashmi","year":"2020","journal-title":"Ann Med Surg"},{"issue":"Pt 1","key":"10.1016\/j.ucl.2025.04.012_bib56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0004563214529937","article-title":"The comparability of oxalate excretion and oxalate:creatinine ratio in the investigation of primary hyperoxaluria: review of data from a referral centre","volume":"52","author":"Clifford-Mobley","year":"2015","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0272-6386(97)90006-8","article-title":"A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymic phenotype, and disease severity","volume":"29","author":"Hoppe","year":"1997","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.ucl.2025.04.012_bib58","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1056\/NEJMra1301564","article-title":"Primary hyperoxaluria","volume":"369","author":"Cochat","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2025.04.012_bib59","article-title":"Primary hyperoxaluria","volume":"2011","author":"Harambat","year":"2011","journal-title":"Internet J Nephrol"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0025-6196(12)60043-3","article-title":"Urolithiasis in pediatric patients","volume":"68","author":"Milliner","year":"1993","journal-title":"Mayo Clin Proc"},{"year":"2020","series-title":"Hereditary Disorders of oxalate metabolism: the primary hyperoxaluria, Oxford textbook of medicine","author":"Fargue","key":"10.1016\/j.ucl.2025.04.012_bib61"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJMc0800990","article-title":"Peculiar morphology of stones in primary hyperoxaluria","volume":"359","author":"Daudon","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib63","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1046\/j.1523-1755.1998.00876.x","article-title":"Crystalluria: a clinically useful investigation in children with primary hyperoxaluria post-transplantation","volume":"53","author":"Jouvet","year":"1998","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib64","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ki.2009.435","article-title":"Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome","volume":"77","author":"Harambat","year":"2010","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ucl.2025.04.012_bib65","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ki.2014.222","article-title":"Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type","volume":"86","author":"Mandrile","year":"2014","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib66","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000085407","article-title":"The primary hyperoxalurias: an algorithm for diagnosis","volume":"25","author":"Milliner","year":"2005","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ucl.2025.04.012_bib67","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clinimag.2018.09.009","article-title":"Imaging features of primary hyperoxaluria","volume":"52","author":"Rootman","year":"2018","journal-title":"Clin Imag"},{"issue":"6","key":"10.1016\/j.ucl.2025.04.012_bib68","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2214\/ajr.183.6.01831767","article-title":"Type 1 primary hyperoxaluria in pediatric patients: renal sonographic patterns","volume":"183","author":"Diallo","year":"2004","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11832-008-0082-4","article-title":"Skeletal features of primary hyperoxaluria type 1, revisited","volume":"2","author":"El Hage","year":"2008","journal-title":"J Child Orthop"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib70","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2214\/ajr.136.5.935","article-title":"Bone changes in end-stage oxalosis","volume":"136","author":"Brancaccio","year":"1981","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib71","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF02011105","article-title":"Oxalosis of bone: report of four cases and a new radiological staging","volume":"25","author":"Fisher","year":"1995","journal-title":"Pediatr Radiol"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib72","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2214\/ajr.146.2.395","article-title":"Radiological aspects of primary hyperoxaluria","volume":"146","author":"Day","year":"1986","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02020832","article-title":"Systemic oxalosis: pathognomonic renal and specific extrarenal findings on US and CT","volume":"25","author":"Akhan","year":"1995","journal-title":"Pediatr Radiol"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib74","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000086360","article-title":"International registry for primary hyperoxaluria","volume":"25","author":"Lieske","year":"2005","journal-title":"Am J Nephrol"},{"issue":"8","key":"10.1016\/j.ucl.2025.04.012_bib75","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00467-006-0124-4","article-title":"Primary hyperoxaluria type 1: still challenging","volume":"21","author":"Cochat","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1523-1755.2001.00462.x","article-title":"Phenotypic expression of primary hyperoxaluria: comparative features of types I and II","volume":"59","author":"Milliner","year":"2001","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ucl.2025.04.012_bib77","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.2215\/CJN.02940608","article-title":"Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure","volume":"3","author":"Nasr","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ucl.2025.04.012_bib78","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.ekir.2020.06.021","article-title":"Etiologies, clinical features, and outcome of oxalate nephropathy","volume":"5","author":"Buysschaert","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1016\/j.ucl.2025.04.012_bib79","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2215\/CJN.00010111","article-title":"Oxalate nephropathy associated with chronic pancreatitis","volume":"6","author":"Cartery","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib80","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semnephrol.2008.01.008","article-title":"The primary hyperoxalurias","volume":"28","author":"Bobrowski","year":"2008","journal-title":"Semin Nephrol"},{"issue":"7","key":"10.1016\/j.ucl.2025.04.012_bib81","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00467-012-2126-8","article-title":"Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn\u2019s disease","volume":"27","author":"Hueppelshaeuser","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ucl.2025.04.012_bib82","first-page":"91","article-title":"Hyperoxaluria and rapid development of renal failure following a combined liver and kidney transplantation: emphasis on sequential transplantation","volume":"3","author":"Alkhunaizi","year":"2012","journal-title":"JIMD Rep"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib83","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2014.10.029","article-title":"Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines","volume":"67","author":"Skolarikos","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib84","doi-asserted-by":"crossref","first-page":"p31","DOI":"10.1159\/000080261","article-title":"Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi","volume":"98","author":"Daudon","year":"2004","journal-title":"Nephron Physiol"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2025.04.012_bib85","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000076583","article-title":"Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis","volume":"72","author":"Marangella","year":"2004","journal-title":"Urol Int"},{"issue":"23","key":"10.1016\/j.ucl.2025.04.012_bib86","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199412083312304","article-title":"Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria","volume":"331","author":"Milliner","year":"1994","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ucl.2025.04.012_bib87","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s11255-018-1939-1","article-title":"Metabolic profile and impact of diet in patients with primary hyperoxaluria","volume":"50","author":"Siener","year":"2018","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"10.1016\/j.ucl.2025.04.012_bib88","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/ki.2008.63","article-title":"[13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria","volume":"73","author":"Sikora","year":"2008","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib89","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000030323","article-title":"Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria","volume":"61","author":"Takei","year":"1998","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MNH.0000000000000790","article-title":"New therapeutics for primary hyperoxaluria type 1","volume":"31","author":"Dejban","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib91","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000085411","article-title":"Implications of genotype and enzyme phenotype in pyridoxine response of patients with type I primary hyperoxaluria","volume":"25","author":"Monico","year":"2005","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib92","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2215\/CJN.06820613","article-title":"Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ucl.2025.04.012_bib93","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ekir.2020.04.004","article-title":"Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (Atypical) AGXT Gene Mutation","volume":"5","author":"Singh","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib94","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1523-1755.2004.00796.x","article-title":"Clinical implications of mutation analysis in primary hyperoxaluria type 1","volume":"66","author":"van Woerden","year":"2004","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib95","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000086358","article-title":"Primary hyperoxaluria--the German experience","volume":"25","author":"Hoppe","year":"2005","journal-title":"Am J Nephrol"},{"issue":"10","key":"10.1016\/j.ucl.2025.04.012_bib96","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s40265-022-01735-x","article-title":"Improving treatment options for primary hyperoxaluria","volume":"82","author":"Hoppe","year":"2022","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.ucl.2025.04.012_bib97","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib98","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.ucl.2025.04.012_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1392644","article-title":"Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial","volume":"12","author":"Frishberg","year":"2024","journal-title":"Front Pediatr"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","article-title":"Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial","volume":"81","author":"Michael","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ucl.2025.04.012_bib101","doi-asserted-by":"crossref","DOI":"10.1007\/s00467-025-06665-w","article-title":"Variable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1","author":"Saffe","year":"2025","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib102","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","article-title":"Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria","volume":"101","author":"Hoppe","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ucl.2025.04.012_bib103","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.urology.2021.03.014","article-title":"Nedosiran dramatically reduces serum oxalate in dialysis-dependent primary hyperoxaluria 1: a compassionate use case report","volume":"156","author":"Shee","year":"2021","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib104","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.ucl.2025.04.012_bib105","doi-asserted-by":"crossref","DOI":"10.1007\/s00467-025-06675-8","article-title":"Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8)","author":"Sas","year":"2025","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib106","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ekir.2024.12.014","article-title":"Concomitant treatment with lumasiran and nedosiran in a child with primary hyperoxaluria type 1","volume":"10","author":"Braekman","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"7","key":"10.1016\/j.ucl.2025.04.012_bib107","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.ekir.2024.04.048","article-title":"Efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1: results from a phase III clinical trial","volume":"9","author":"Saland","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib108","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ndt\/gfac295","article-title":"Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases","volume":"38","author":"Sellier-Leclerc","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.kint.2021.10.022","article-title":"Early post-transplant recurrence of oxalate nephropathy in a patient with primary hyperoxaluria type 1, despite pretransplant lumasiran therapy","volume":"101","author":"Joher","year":"2022","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ucl.2025.04.012_bib110","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00467-016-3324-6","article-title":"Pediatric combined liver-kidney transplantation: a single-center experience of 18 cases","volume":"31","author":"Duclaux-Loras","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib111","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ekir.2023.10.004","article-title":"Multicenter long-term real world data on treatment with lumasiran in patients with primary hyperoxaluria type 1","volume":"9","author":"Martin-Higueras","year":"2024","journal-title":"Kidney Int Rep"},{"year":"2025","series-title":"Hemodialysis","author":"Murdeshwar","key":"10.1016\/j.ucl.2025.04.012_bib112"},{"issue":"12","key":"10.1016\/j.ucl.2025.04.012_bib113","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1093\/ndt\/16.12.2407","article-title":"Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1","volume":"16","author":"Yamauchi","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib114","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1046\/j.1523-1755.1999.00546.x","article-title":"Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure","volume":"56","author":"Hoppe","year":"1999","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ucl.2025.04.012_bib115","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/sj.ki.5001806","article-title":"Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1","volume":"70","author":"Illies","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib116","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/ajt.12535","article-title":"Auxiliary liver transplant is an ineffective treatment of primary hyperoxaluria","volume":"14","author":"Trotter","year":"2014","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ucl.2025.04.012_bib117","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00467-021-05043-6","article-title":"Transplantation outcomes in patients with primary hyperoxaluria: a systematic review","volume":"36","author":"Metry","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.ucl.2025.04.012_bib118","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/lt.24009","article-title":"Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience","volume":"20","author":"Compagnon","year":"2014","journal-title":"Liver Transplant"},{"issue":"11","key":"10.1016\/j.ucl.2025.04.012_bib119","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1053\/jlts.2001.28741","article-title":"Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria","volume":"7","author":"Monico","year":"2001","journal-title":"Liver Transplant"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ekir.2021.11.006","article-title":"Long-term transplantation outcomes in patients with primary hyperoxaluria type 1 included in the european hyperoxaluria consortium (OxalEurope) Registry","volume":"7","author":"Metry","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1016\/j.ucl.2025.04.012_bib121","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/TP.0b013e3181a27939","article-title":"Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth","volume":"87","author":"Brinkert","year":"2009","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib122","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/tomography7040051","article-title":"Implementation of a Technique Based on Hounsfield Units and Hounsfield Density to Determine Kidney Stone Composition","volume":"7","author":"Rodriguez-Plata","year":"2021","journal-title":"Tomography"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib123","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00345-020-03241-9","article-title":"How do we assess the efficacy of Ho:YAG low-power laser lithotripsy for the treatment of upper tract urinary stones? Introducing the Joules\/mm(3) and laser activity concepts","volume":"39","author":"Ventimiglia","year":"2021","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib124","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11934-023-01145-w","article-title":"Role of hounsfield unit in predicting outcomes of shock wave lithotripsy for renal calculi: outcomes of a systematic review","volume":"24","author":"Garg","year":"2023","journal-title":"Curr Urol Rep"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/EJA.0000000000001599","article-title":"Pre-operative fasting in children: a guideline from the European Society of Anaesthesiology and Intensive care","volume":"39","author":"Frykholm","year":"2022","journal-title":"Eur J Anaesthesiol"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib126","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.urology.2014.11.018","article-title":"Surgical management of stone disease in patients with primary hyperoxaluria","volume":"85","author":"Carrasco","year":"2015","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109530","article-title":"Restored glyoxylate metabolism after AGXT gene correction and direct reprogramming of primary hyperoxaluria type 1 fibroblasts","volume":"27","author":"Nieto-Romero","year":"2024","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ymthe.2024.11.031","article-title":"Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption","volume":"33","author":"Jiang","year":"2025","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s44321-023-00008-8","article-title":"Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1","volume":"16","author":"Torella","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"40","key":"10.1016\/j.ucl.2025.04.012_bib130","doi-asserted-by":"crossref","first-page":"14406","DOI":"10.1073\/pnas.1408401111","article-title":"Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1","volume":"111","author":"Miyata","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.ucl.2025.04.012_bib131","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1159\/000533295","article-title":"Oxalate nephropathy and the mechanism of oxalate-induced kidney injury","volume":"9","author":"Bao","year":"2023","journal-title":"Kidney Dis"},{"issue":"7","key":"10.1016\/j.ucl.2025.04.012_bib132","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.ki.5001707","article-title":"Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1","volume":"70","author":"Hoppe","year":"2006","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.ucl.2025.04.012_bib133","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.ajkd.2011.05.012","article-title":"Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis","volume":"58","author":"Hoppe","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1016\/j.ucl.2025.04.012_bib134","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1093\/ndt\/gfr107","article-title":"Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria","volume":"26","author":"Hoppe","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib135","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00467-016-3553-8","article-title":"A randomised Phase I\/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria","volume":"32","author":"Hoppe","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1016\/j.ucl.2025.04.012_bib136","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/ndt\/gfaa135","article-title":"Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study","volume":"36","author":"Hoppe","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.ucl.2025.04.012_bib137","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00240-005-0497-z","article-title":"Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria?","volume":"33","author":"Hoppe","year":"2005","journal-title":"Urol Res"},{"issue":"4","key":"10.1016\/j.ucl.2025.04.012_bib138","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00240-017-0998-6","article-title":"A randomised Phase II\/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria","volume":"46","author":"Milliner","year":"2018","journal-title":"Urolithiasis"},{"key":"10.1016\/j.ucl.2025.04.012_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2025.02.004","article-title":"Inducing Oxalobacter formigenes colonization reduces urinary oxalate excretion in healthy adults","author":"Fargue","year":"2025","journal-title":"Kidney Int Reports"},{"issue":"7","key":"10.1016\/j.ucl.2025.04.012_bib140","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100053","article-title":"Randomized placebo-controlled trial of reloxaliase in enteric hyperoxaluria","volume":"1","author":"Lieske","year":"2022","journal-title":"NEJM Evidence"},{"issue":"2","key":"10.1016\/j.ucl.2025.04.012_bib141","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ekir.2024.11.020","article-title":"A targeted release capsule of lanthanum carbonate: a new efficient cheap treatment for primary hyperoxalurias","volume":"10","author":"De Broe","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.ucl.2025.04.012_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166848","article-title":"Therapeutic targeting of HYPDH\/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity","volume":"1870","author":"Bons","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:18:43Z","timestamp":1751545123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":142,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0094014325000400"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.04.012","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperoxaluria","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}